Leukotriene B₄ inhibitors: US2009054466; US2009227603 and US2009253684

Bibliography

• Samuelsson B. The discovery of the leukotrienes. Am J Respir Crit Care Med 2000;161:s2-6
   PubMed Web of Science ®Google Scholar
• Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B4 receptors. Prostaglandins Leukot Essent Fatty Acids 2003;69:123-34
   PubMed Web of Science ®Google Scholar
• Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007;357(18):1841-54
   PubMedGoogle Scholar
• Maekawa A, Kanaoka Y, Xing W, Austen KF. Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci USA 2008;105(43):16695-700
   PubMedGoogle Scholar
• Nonaka Y, Hiramoto T, Fujita N. Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun 2005;337:281-8
   PubMedGoogle Scholar
• Hicks A, Monkarsh SP, Hoffman AF, Goodnow R Jr. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin Investig Drugs 2007;16(12):1909-20
   PubMedGoogle Scholar
• Okuno T, Iizuka Y, Okazaki H, 12(S)-hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J Exp Med 2008;205(4):759-66
   PubMedGoogle Scholar
• Cho K-J, Seo J-M, Shin Y-H, Blockade of airway inflammation and hyperresponsiveness by inhibition of BLT2, a low affinity leukotriene B4 receptor. Am J Respir Cell Mol Biol 2009. [Epub ahead of print]
   Google Scholar
• Korea University Industrial & Academic Collaboration Foundation. Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma. WO2008117971
   Google Scholar
• Kim HJ, Kim DK, Kim H, Involvement of the BLT2 receptor in te itch-associated scratching induced by 12-lipoxygenase products in ICR mice. Br J Pharmacol 2008;154:1073-8
   PubMedGoogle Scholar
• Xu S, Lu H, Chen Z, Jiang D. Regulation of TNFalpha and IL1beta in rheumatoid arthritis synovial fibroblasts by leukotriene B4. Rheumatol Int Published online 07 October 2009
   Google Scholar
• Kim G-Y, Lee J-W, Cho S-H, Role of the low-affinity leukotriene B4 receptor BLT2 in VEGF-induced angiogenesis. Arterioscler Thromb Vasc Biol 2009;29:915-20
   PubMedGoogle Scholar
• Korea University Industrial & Academic Collaboration Foundation. Use of inhibitors of leukotriene B4 receptor BLT2 for treating human cancers. WO2008117970
   Google Scholar
• Hennig R, Osman T, Esposito I, BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumor cell proliferation. Br J Cancer 2008;99:1064-73
   PubMedGoogle Scholar
• Rocconi RP, Kirby TO, Beck R, Lipoxygenase pathway receptor expression in ovarian cancer. Reprod Sci 2008;15(3):321-6
   PubMedGoogle Scholar
• Kim EY, Seo JM, Cho KJ, Kim JH. Ras-induced invasion and metastasis are regulated by a leukotriene B(4) receptor BLT2-linked pathway. Oncogene 2009. Published online 23 November 2009
   Google Scholar
• Kishikawa K, Tateishi N, Maruyama T, ONO-4057, a novel, orally active leukotriene B4 antagonist: effects on LTB4-induced neutrophil functions. Prostaglandins 1992;44:261-75
   PubMedGoogle Scholar
• Yokomizo T, Kato K, Terawaki K, A second leukotriene B4 receptor, BLT2: a new therapeutic target in inflammation and immunological disorders. J Exp Med 2000;192:421-32
   PubMed Web of Science ®Google Scholar
• Birke FW, Meade J, Anderskewitz R, In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B4 receptor antagonist. J Pharmacol Exp Ther 2001;297:458-66
   PubMed Web of Science ®Google Scholar
• Diaz-Gonzalez F, Alten RHE, Bensen WG, Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:628-32
   PubMed Web of Science ®Google Scholar
• Diaz-Gonzalez F, Alten RHE, Bensen WG, Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:628-32
   PubMed Web of Science ®Google Scholar
• Konstan MW, Doring G, Lands LC, Results of a phase II clinical trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of CF lung disease. Pediatr Pulmonol 2005;s28:125-6
   Google Scholar
• Effect of a 14-day treatment with BIIL 284 BS on patients with COPD (double-blind, placebo-controlled, randomized, parallel study). Royal Brompton & Harefield NHS. Available from: www.rbht.nhs.uk/research/projects/rss/?EntryId31=45041
   Google Scholar
• Yokomizo Y, Izumi T, Shimizu T. Leukotriene B4: metabolism and signal transduction. Arch Biochem Biophys 2001;385:231-41
   PubMed Web of Science ®Google Scholar
• Gaber F, James A, Delin I, Assessment of in vivo 5-lipoxygenase activity by analysis of leukotriene B4 in saliva: effects of treatment with zileuton. J Allergy Clin Immunol 2007;119(5):1267-8
   PubMedGoogle Scholar
• Hui KP, Taylor IK, Taylor GW, Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991;46:184-9
   PubMed Web of Science ®Google Scholar
• Nasser SMS, Bell GS, Hawksworth RJ, Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. Thorax 1994;49:743-8
   PubMed Web of Science ®Google Scholar
• McGill KA, Busse WW, Zileuton I. 1996;348:519-24
   Google Scholar
• Evans JF, Ferguson AD, Mosley RT, Hutchinson JH. What's all the FLAP about?: 5-lipoygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 2008;29:72-8
   PubMed Web of Science ®Google Scholar
• Yokomiso T, Kato K, Hagiyu H, Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem 2001;276(15):12454-9
   PubMedGoogle Scholar
• Ando K, Tsuji E, Ando Y, Preparation of 2- and 4-(2-alkylcarbamoyl-1-methylvinyl)-7-alkoxybenzo[b]furans having potent antagonistic activity against human leukotriene B4 BLT1 and/or BLT2 receptors. Org Biomol Chem 2004;2:3427-31
   PubMed Web of Science ®Google Scholar
• Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev 2005;4:664-72
   Google Scholar
• Helgadottir A, Manolescu A, Helgason A, A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006;38:68-74
   PubMed Web of Science ®Google Scholar
• Back M. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr Pharm Des 2009;15(27):3116-32
   PubMedGoogle Scholar
• Mehrabian M, Allayee H, Wong J, Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002;91:120-6
   PubMed Web of Science ®Google Scholar
• Rossoni G, Sala A, Berti F, Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J Pharmacol Exp Ther 1996;276:335-41
   PubMed Web of Science ®Google Scholar
• Whatling C, McPheat W, Herslof M. The potential link between athersclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field. Expert Opin Investig Drugs 2007;16:1879-93
   PubMed Web of Science ®Google Scholar
• Tardiff J-C, L'Allier PL, Ibrahim R, Three months of treatment with 5-lipoxygenase inhibitor VIA-2291 in patients with recent acute coronary syndrome. Circulation 2008;118(22):2314
   Google Scholar
• Via Pharmaceuticals. VIA's lead compound: VIA-2291. Available from: www.viapharmaceuticals.com/via-2291
   Google Scholar
• GSK Product Development Pipeline February 2009. Available from: www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf
   Google Scholar
• Austen KF, Maekawa A, Kanaoka Y, Boyce JA. The leukotriene E4 puzzle: Finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol 2009;124(3):406-14
   PubMedGoogle Scholar
• Lee TH, Woszczek G, Farooque SP. Leukotriene E4: perspective on the forgotten mediator. J Allergy Clin Immunol 2009;124(3):417-21
   PubMedGoogle Scholar
• Fischer L, Steinhilber D, Werz O. Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Br J Pharmacol 2004;142:861-8
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. Pyrazole analogs. WO2008065493
   Google Scholar
• Pfizer, Inc. Pyrazole derivatives as 5-LO inhibitors. WO2009069044
   Google Scholar
• The effect of MK0633 in patients with chronic asthma. Clinical Trials.gov. Available from: www.clinicaltrials.gov/ct2/show/NCT00404313?term=MK0633&rank=4205
   Google Scholar
• Janssen Pharmaceuticals NV. Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase. WO2009058347
   Google Scholar
• Janssen Pharmaceuticals NV. Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase. WO2009126806
   Google Scholar
• Fourie AM. Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase. Curr Opin Investig Drugs 2009;10(11):1173-82
   PubMedGoogle Scholar
• Zileuton to treat adults with chronic obstructive pulmonary disease (the LEUKO Study). ClinicalTrials.gov. Available from: www.clinicaltrial.gov/ct2/show/NCT00493974
   Google Scholar